The clinical success of the two BTK inhibitors, ibrutinib and acalabrutinib, represents a major
breakthrough in the treatment of chronic lymphocytic leukemia (CLL) and has also …

The BTK inhibitors ibrutinib and acalabrutinib are FDA-approved drugs for the treatment of B
cell malignances. Both drugs have demonstrated clinical efficacy and safety profiles superior …

Bruton´ s tyrosine kinase (BTK) inhibitor (BTKi) s block the B-cell receptor (BCR) signaling
cascade by binding to the BTK enzyme preventing the proliferation and survival of malignant …

Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of
patients with relapsed/refractory or treatment-naïve chronic lymphocytic leukemia (CLL) …

BACKGROUND. Ibrutinib has been shown to have immunomodulatory effects by inhibiting
Bruton's tyrosine kinase (BTK) and IL-2–inducible T cell kinase (ITK). The relative …

Chronic lymphocytic leukemia (CLL), a highly heterogeneous B-cell malignancy, is
characterized by tumor microenvironment disorder and T-cell immune dysfunction, which …

Autoimmune cytopenia (AIC) represents a clinical challenge in about 5–10% of patients with
chronic lymphocytic leukemia (CLL) at some point during the course of their disease. 1–3 …

Small molecule inhibitors targeting dysregulated pathways (RAS/RAF/MEK,
PI3K/AKT/mTOR, JAK/STAT) have significantly improved clinical outcomes in cancer …

Ibrutinib positively modulates many T-cell subsets in chronic lymphocytic leukemia (CLL). To
understand ibrutinib's effects on the broader landscape of immune cell populations, we …

B cell receptor (BCR) stimulation signal plays an important role in the pathogenesis of
chronic lymphocytic leukemia (CLL), and kinase inhibitors directed toward the BCR pathway …